Disease/Infection News

RSS

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

President Obama's commitment to global AIDS and health is in doubt: GAA

Later today, Ambassador Eric Goosby will be sworn in as the U.S. Global AIDS Coordinator. "While we welcome Ambassador Goosby to his new post, and look forward to working with him on a broad range of issues that affect the health and well-being of the world's vulnerable populations, there are a number of as-yet unanswered questions about the true commitment of the Obama Administration to global AIDS and health, including PEPFAR [President's Emergency Plan for AIDS Relief]," said Dr. Paul Zeitz, GAA executive director.

18 Sep 2009

Quebec research on contagious period of H1N1 patients to be presented

Members of a group of Quebec researchers will be presenting the preliminary results of their work on Influenza A (H1N1) tomorrow at the Interscience Conference on Antimicrobial Agents and Chemotherapy, a prestigious international conference that the American Microbiology Association is currently presenting in San Francisco.

18 Sep 2009

Research reveals binge drinking weakens the body's ability to fight off infection

As if a bad hangover wasn't enough of a deterrent, new research has shown how binge drinking weakens the body's ability to fight off infection for at least 24 hours afterwards. The study, published today in the open access journal BMC Immunology, focused on the effect of heavy drinking on toll-like receptor 4 (TLR4), a protein that has an important role in immune system activation.

17 Sep 2009

A not-for-profit mission from Wellcome Trust and Merck to develop affordable vaccines for low-income countries

The Wellcome Trust and Merck & Co., Inc. today announced the creation of the MSD Wellcome Trust Hilleman Laboratories (www.hillemanlaboratories.in), the first of its kind research and development joint venture with a not-for-profit mission to focus on developing affordable vaccines to prevent diseases that commonly affect low-income countries.

17 Sep 2009

New CLF survey on the unawareness of Canadians in contracting food-related illnesses

A new survey from the Canadian Liver Foundation (CLF) reveals more than half of Canadians over the age of 25 (57 per cent) are concerned about contracting food-related illnesses like hepatitis A, but many are unaware that their everyday food preparation and consumption habits may put them at risk for this liver disease

17 Sep 2009

Discovery of key molecule may yield new therapies for AIDS and cancer

Discovery by Hebrew University of Jerusalem researchers of an additional role for a key molecule in our bodies provides a further step in world-wide efforts to develop genetic regulation aimed at controlling many diseases, including AIDS and various types of cancers.

17 Sep 2009

Mexico fights H1N1 cases with Polycom visual communication systems

As the world braces for the coming winter flu season, health officials in Mexico expect to battle an anticipated rise in H1N1 flu cases with interactive visual communication systems from Polycom, the global leader in telepresence, video and voice communication solutions.

17 Sep 2009

TOWN HALL Los Angeles hosts panel discussion on H1N1 outbreak preparedness

"Hand Washing, Not Hand-Wringing: Preparing for H1N1" is the subject of a panel discussion hosted by TOWN HALL Los Angeles on Wednesday, September 23, 2009 at the National Center for the Preservation of Democracy in downtown Los Angeles.

17 Sep 2009

Research study on Lyme disease

Potentially debilitating Lyme disease doesn't afflict people everywhere that the ticks harboring it are found. At least not yet. A five-university consortium led by a Michigan State University researcher wants to find out why.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

Fully-insured members of Capital BlueCross to receive coverage for administration fee for H1N1 Flu vaccine

Capital BlueCross announced today that it will cover an administration fee for the H1N1 Flu vaccine for fully-insured members and those with individual coverage during the upcoming 2009-2010 flu season. Self-funded groups may opt to have their coverage customized to include this benefit.

17 Sep 2009

Researchers investigate individual's ability to get rid of Hepatitis C

More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.

17 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu) vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign, The Wall Street Journal reports. The application for GlaxoSmithKline PLC's vaccine is still being considered (Dooren/Favole, 9/15).

17 Sep 2009

HIRC investigates the impact of infrastructure on pathogens and micro-organisms

The spread of swine flu and other infectious diseases could be dramatically reduced by revolutionising the way that the places we live in are designed and built.

17 Sep 2009

Administrative cost of H1N1 vaccine to be covered for CIGNA's customers

The spread of the H1N1 influenza virus has the potential to make this year’s flu season more severe than usual. The Centers for Disease Control and Prevention (CDC) has designated vaccination as the most powerful public health tool to control influenza.

17 Sep 2009

Researchers discover HIV Nef protein's role in cell mobility inhibition

In order to be able to ward off disease pathogens, immune cells must be mobile and be able to establish contact with each other. The working group around Professor Dr. Oliver Fackler in the Virology Department of the Hygiene Institute of the Heidelberg University Hospital has discovered a mechanism in an animal model revealing how HIV, the AIDS pathogen, cripples immune cells: Cell mobility is inhibited by the HIV Nef protein.

17 Sep 2009

H1N1 influenza prevention campaign launched

Children's Hospital of Wisconsin today announced the launch of an H1N1 influenza prevention campaign geared toward informing educators, parents, caregivers and children of all ages on the importance of practicing healthy habits this cold and flu season.

17 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009